8-K: Sensus Healthcare Reports Q4 Loss, Eyes 2026 Profitability

Sensus Healthcare announced its fourth quarter and full-year 2025 financial results, reporting significant losses but expressing optimism for 2026 profitability driven by new dedicated CPT codes for SRT.

Summary

• Revenues for the fourth quarter of 2025 were $4.9 million, a decrease from $13.1 million in the fourth quarter of 2024.
• Full-year 2025 revenues totaled $27.5 million, down from $41.8 million in 2024.
• The company reported a net loss of $3.2 million, or $0.19 per share, for Q4 2025, compared to a net income of $1.5 million, or $0.09 per diluted share, in Q4 2024.
• For the full year 2025, Sensus Healthcare posted a net loss of $7.7 million, or $0.47 per share, a reversal from net income of $6.6 million, or $0.41 per diluted share, in 2024.
• Adjusted EBITDA was negative $3.0 million for Q4 2025 and negative $9.6 million for the full year 2025.
• Sensus Healthcare shipped 14 superficial radiotherapy (SRT) systems in Q4 2025, an increase from six systems in Q3 2025 (excluding shipments to its historically largest customer).
• The company ended 2025 with $22.1 million in cash and cash equivalents and no debt.
• The Fair Deal Agreement (FDA) program expanded significantly, delivering 11,411 treatments to 922 patients in 2025, an eight-fold increase in treatments compared to 2024.
• Management anticipates sequential-quarter revenue growth in Q1 2026 and expects to achieve full-year profitability in 2026, primarily due to new dedicated CMS reimbursement codes for SRT technology.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While 2025 financial performance was significantly worse year-over-year, the establishment of dedicated CPT codes with a 300% reimbursement increase for SRT, effective January 1, 2026, provides a strong positive catalyst and clear path to expected profitability in 2026.

Positives

• Publication of dedicated CPT codes for SRT to treat non-melanoma skin cancer in November, with a 300% per-fraction increase to the delivery code, effective January 1, 2026.
• Entered 2026 with reimbursement certainty and strategic visibility due to the new dedicated CMS reimbursement codes.
• Shipped 14 SRT systems in Q4 2025, an increase from six systems in Q3 2025 (excluding the historically largest customer), indicating sequential improvement in unit sales.
• Ended the year with a strong balance sheet, including $22.1 million in cash and cash equivalents and no outstanding debt.
• Significant expansion of the Fair Deal Agreement (FDA) program, with 18 active sites and 10 sites pending activation as of year-end, and an eight-fold increase in treatments delivered (11,411 in 2025 vs. 1,367 in 2024).
• International demand contributed meaningfully to Q4 2025, including shipments to China, highlighting international markets as an important growth component.
• Management expects sequential-quarter revenue growth in Q1 2026 and projects full-year profitability for 2026.
• New reimbursement rates served as catalysts for system purchases by FDA customers.

Negatives

• Revenues for Q4 2025 decreased significantly to $4.9 million from $13.1 million in Q4 2024.
• Full-year 2025 revenues decreased to $27.5 million from $41.8 million in 2024.
• The company reported a net loss of $3.2 million in Q4 2025, a reversal from a net income of $1.5 million in Q4 2024.
• Full-year 2025 saw a net loss of $7.7 million, compared to a net income of $6.6 million in 2024.
• Adjusted EBITDA was negative $3.0 million for Q4 2025 and negative $9.6 million for the full year 2025, a significant decline from positive Adjusted EBITDA in 2024.
• Gross profit margin decreased to 38.8% in Q4 2025 from 54.2% in Q4 2024, and to 43.3% for full-year 2025 from 58.4% in 2024.
• The decrease in revenue and gross profit was primarily driven by a lower number of units sold, reflecting reduced sales to the company's largest customer.
• Research and development expenses increased significantly in 2025 to $7.8 million from $4.2 million in 2024, partly due to lobbying costs related to billing code reimbursement.
• Selling and marketing expenses increased in 2025 to $6.5 million from $5.0 million in 2024 due to higher tradeshow and payroll costs.

Risks

• The possibility that inflationary pressures continue to impact sales.
• The level and availability of government and/or third-party payor reimbursement for clinical procedures using products, and the willingness of healthcare providers to purchase products if the level of reimbursement declines.
• Concentration of customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.
• The development by others of new products, treatments, or technologies that render Sensus Healthcare's technology partially or wholly obsolete.
• Regulatory requirements applicable to Sensus Healthcare and its competitors.
• Ability to efficiently manage manufacturing processes and costs.
• Risks arising from doing business in China and other foreign countries.
• Legislation, regulation, or other governmental action that affects products, taxes, international trade regulation (including the possibility of tariffs on equipment exported or materials imported).
• The performance of the company's information technology systems and its ability to maintain data security.
• Ability to obtain and maintain the intellectual property needed to adequately protect products, and ability to avoid infringing or otherwise violating the intellectual property rights of third parties.
• Geopolitical uncertainties, though those other than relating to China have not had any significant impact on the business to date.

Future Outlook

Sensus Healthcare anticipates sequential-quarter revenue growth in the first quarter of 2026, driven by its current pipeline and order activity, without contribution from its historically largest customer. The company expects to achieve full-year profitability in 2026, leveraging the new dedicated CMS reimbursement codes, a more diversified customer base, new international opportunities, and continued tight expense management. Management also plans to hire several new sales representatives to capitalize on the improved operating environment.

Management Comments

• "Following the publication of Current Procedural Terminology (CPT) codes for treating non-melanoma skin cancer with SRT in November — with a per-fraction increase of more than 300% versus prior delivery code — and despite a very tight subsequent selling window in the midst of multiple holidays, we shipped 14 systems in Q4 without any contribution from our historically largest customer, compared with six units in Q3 excluding shipments to that customer."
• "With dedicated reimbursement codes now in place, a strong balance sheet with no debt and significantly enhanced physician economics, we look forward to 2026 with greater business control, predictability, and optimism."
• "FDA utilization increased significantly in 2025, with treatments up more than eight-fold versus 2024 and the number of patients treated up by more than 250%. In several cases, the new reimbursement rates served as catalysts for system purchases by FDA customers."
• "International demand contributed meaningfully to the fourth quarter with shipments to China, and international markets remain an important component of our growth strategy."
• "Looking to the first quarter of 2026, based on our current pipeline and order activity we expect shipments to exceed fourth quarter 2025 levels without any contribution from our historically largest customer. More broadly, 2026 represents a new operating environment for Sensus, one we intend to fully leverage including by hiring several new sales reps."
• "With attractive reimbursement, a more diversified customer base, new international opportunities and a continued commitment to tight expense management, our objective is to achieve full-year profitability."

Industry Context

StockSavvy.ai notes that the medical device industry, particularly in specialized areas like oncology and dermatology, is highly sensitive to reimbursement policies. The significant increase in CMS reimbursement for SRT procedures positions Sensus Healthcare favorably, potentially accelerating adoption and market penetration for its non-invasive skin cancer treatments. This development could provide a competitive edge against alternative treatment modalities and other device manufacturers, especially as healthcare providers seek cost-effective and efficient solutions with clear reimbursement pathways. The focus on international expansion, particularly in China, aligns with broader trends of medical device companies seeking growth in emerging markets.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Sensus Healthcare's performance against global benchmarks.
• However, the 300% per-fraction increase in the CMS delivery code for SRT is a substantial positive development that could significantly improve the economics for healthcare providers utilizing Sensus Healthcare's technology, potentially making it more competitive against other treatment options for non-melanoma skin cancer.

Stakeholder Impact

• Shareholders: Experienced significant losses in 2025, but the positive outlook for 2026, driven by improved reimbursement and expected profitability, could lead to future value creation.
• Customers (Healthcare Providers): Benefit from significantly enhanced physician economics due to the 300% per-fraction increase in CMS reimbursement for SRT, making Sensus Healthcare's technology more attractive for treating non-melanoma skin cancer.
• Employees: Potential for increased headcount with plans to hire new sales reps, indicating growth and stability.
• Suppliers: Continued demand for SRT systems, especially with expected sequential revenue growth, could benefit suppliers.
• Creditors: The company has no debt and $22.1 million in cash, indicating a strong financial position from a credit perspective.

Next Steps

• Leverage the new operating environment in 2026, including hiring several new sales representatives.
• Achieve full-year profitability in 2026.
• Continue to monitor geopolitical uncertainties, addressing them in future filings if applicable.
• Host an investment community conference call on February 12, 2026, at 4:30 p.m. Eastern time.

Key Dates

Recommendation

While Sensus Healthcare reported a significant net loss and revenue decline for 2025, the establishment of new, highly favorable CMS reimbursement codes for SRT, effective January 1, 2026, fundamentally alters the company's future revenue and profitability potential. Management's guidance for sequential Q1 2026 revenue growth and full-year 2026 profitability, coupled with a strong balance sheet (no debt, $22.1 million cash), suggests a strong turnaround is anticipated. However, the actual execution of this turnaround and the realization of the benefits from the new codes need to be monitored. The stock is a 'hold' as investors should observe the Q1 2026 results to confirm the positive impact of the new reimbursement structure before making a stronger commitment, given the poor 2025 performance.

Keywords

Sensus Healthcare, SRTS, Financial Results, Q4 2025, Full Year 2025, SEC Filing, 8-K, Medical Device, Skin Cancer Treatment, SRT Technology, CPT Codes, CMS Reimbursement, Non-Melanoma Skin Cancer, Fair Deal Agreement, FDA Program, Superficial Radiotherapy, Oncology, Dermatology, Financial Performance, Earnings Report